Published in:
01-08-2008 | Gastrointestinal Oncology
Comparison of Central and Extended Left Pancreatectomy for Lesions of the Pancreatic Neck
Authors:
Lee M. Ocuin, MD, Juan M. Sarmiento, MD, Charles A. Staley, MD, John R. Galloway, MD, Colin D. Johnson, MD, William C. Wood, MD, David A. Kooby, MD
Published in:
Annals of Surgical Oncology
|
Issue 8/2008
Login to get access
Abstract
Background
Central pancreatectomy (CP) is a parenchyma-sparing alternative to extended left pancreatectomy (ELP) for tumors of the pancreatic neck. We compared short- and long-term outcomes for the two approaches.
Methods
Patients who underwent CP or ELP from 2000–2007 for neoplasms of the neck were identified. Charts were reviewed for patient, treatment, and outcome data. Long-term and quality-of-life (QoL) data were gathered through Institutional Review Board (IRB)-approved telephone interviews and questionnaires European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, and QLQ-PAN26.
Results
31 patients were identified; 13 underwent CP and 18 underwent ELP. Median follow-up was 29 months (range 5–90). Groups did not differ in age, American Society of Anesthesiologists (ASA) class, or preexisting diabetes mellitus (DM). CP patients had less gland resected (5.7 ± 2.1 cm versus 10.8 ± 2.8 cm) and lower postoperative mean blood glucose levels (120 ± 15 mg/dl versus 136 ± 24 mg/dl). CP patients experienced more complications (92% versus 39%), but no significant difference in major complications (38%, CP versus 17%, ELP; P = 0.17) or hospital stay (9 ± 3 days, CP versus 7.5 ± 4 days, ELP). There was one perioperative death in the CP group, unrelated to surgical technique. Questionnaire analysis showed no differences in functional or symptom scales. New-onset exocrine insufficiency was not significantly different between the groups (10%, CP versus 27%, ELP; P = 0.62), but the ELP group had a higher rate of new-onset DM (57% versus 11%; P = 0.04).
Conclusion
CP is associated with more complications than ELP, but no difference in long-term QoL. Due to the lower incidence of postoperative DM, CP can be recommended for healthy patients with indolent tumors of the pancreatic neck.